prnewswire.comJUN 42 min read$ASTH

Astrana Health Named to the 2026 Fortune 1000 List Following Strong Revenue Growth

Astrana Health (NASDAQ: ASTH) said it was named to the 2026 Fortune 1000, debuting on the list of the largest U.S. companies by revenue. The company reported fiscal 2025 revenue of $3.18 billion (+56% y/y), adjusted EBITDA of $205.4 million, and free cash flow of $104.5 million. Astrana supports 20,000+ providers and 1.55 million patients in value-based care.

Original reporting

prnewswire.com

Published Jun 4, 2026, 9:30 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Jun 4, 2026, 9:57 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Source · prnewswire.com

Decision brief

The 30-second read

$ASTHBullishLow

Why it matters

The announcement emphasizes growth metrics (FY2025 revenue up 56%) and AI-powered infrastructure positioning, which can support sentiment but does not introduce new forward-looking commitments.

Market read

For ASTH, the main tradable element is incremental visibility/credibility; fundamentals appear unchanged because FY2025 figures are already referenced in the release.

What to watch

Traders may discount PR announcements unless paired with updated guidance, contract wins, or measurable KPI changes beyond FY2025 results.

Relevance 6/10Novelty 4/10Timing: after-hours PR release (June 4, 2026)

Background

Fortune 1000 ranks the largest US companies by revenue; Astrana is debuting on the list for 2026.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ASTHBullishMedium confidence

Context

Astrana was named to the 2026 Fortune 1000 debut, highlighting 56% FY2025 revenue growth and AI-enabled healthcare infrastructure momentum.

Expected impact

Likely limited near-term impact; any move would be sentiment/flow-driven rather than fundamentals-changing.

Evidence & confidence

The article is a PR-style announcement with no guidance change, deal, or regulatory event; it reiterates FY2025 revenue/EBITDA/FCF and frames growth/AI strategy.

Market effects

Sector

Reinforces investor narrative that physician-centric, value-based care platforms with AI infrastructure are scaling.

Regional

No specific regional catalyst beyond company visibility.

Global

Primarily US visibility/benchmarking; limited direct global read-through.

Counterpoint

What could challenge this read

Fortune 1000 inclusion may not translate into incremental demand or earnings power; it can be largely ceremonial versus operational catalysts.

Key entities

company
Astrana Health, Inc.
Named to the 2026 Fortune 1000; highlights FY2025 revenue growth and AI-enabled healthcare infrastructure strategy.

Read at source ← All news

AUG 13

$ASTHMedAI 8/10

Astrana Health (ASTH) Q2 2026 Earnings Call Transcript

Astrana Health (ASTH) reported Q2 2026 revenue of $972.5M, up 49% YoY, and adjusted EBITDA of $68.9M, up 43%. Adjusted EPS was $0.80. Six-month free cash flow was $92.9M. The company reaffirmed full-year revenue guidance of $3.8B to $4.1B and raised adjusted EBITDA guidance to $255M to $280M. Net leverage was 2.26.

fool.com7 min

AUG 7

$ASTHMedAI 8/10

Astrana Health Inc (ASTH) (Q2 2026) Earnings Call Highlights: Record EPS and Raised

Astrana Health Inc (ASTH) reported Q2 2026 results with record EPS and raised guidance, according to management on its earnings call. The company cited a one-time $15 million Q2 revenue reduction tied to CMS adjustments for ACO REACH 2025 billing, with immaterial net EBITDA impact. It also discussed Medicaid membership attrition, commercial cost trends, and wide Q4 2026 EBITDA guidance of $47-$67 million.

yahoo.com4 min

AUG 6

$ASTHMed

Astrana Health (NASDAQ:ASTH) Beats Q2 CY2026 Non

Astrana Health (NASDAQ:ASTH) reported Q2 CY2026 revenue of $972.5 million, up 48.5% year on year but below market expectations. Next-quarter revenue guidance was $1.02 billion, about 1.1% under analysts’ estimates. Non-GAAP EPS was $0.80, up 9.6% versus consensus. Shares rose 5.1% to $35.89 after results.

financialcontent.com6 min

AUG 6

$ASTHHigh

Astrana Health, Inc. (ASTH): Results of Operations and Financial Condition

Astrana Health, Inc. (ASTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622348d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Astrana Health, Inc. Reports Second Quarter 2026 Results Company to Host Conference Call on Thursday, August 6, 2026, at 2:30 p.m. PT/5:30 p.m. ET · Reports revenue of $972.5 million, up 49% year-over-year, net income of

SEC EDGAR 8-K6 min

AUG 23

$MRKHighAI 9/10

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.

genengnews.com3 min